Skip to main content

Clinical Trials Using Cytarabine

Review the clinical trials studying cytarabine on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 51-75 of 107

Venetoclax with Standard Remission Induction Chemotherapy for the Treatment of Patients with Secondary Acute Myeloid Leukemia
Status: Active
Location: University of Michigan Rogel Cancer Center, Ann Arbor, Michigan
Cladribine, Low Dose Cytarabine, Venetoclax, and Azacitidine for the Treatment of Higher-Risk Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia or Myelodysplastic Syndrome/Myeloproliferative Neoplasms
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients with Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Induction and Consolidation with Fludarabine, Cytarabine, Idarubicin, and Venetoclax for the Treatment of Acute Myeloid Leukemia
Status: Active
Location: OHSU Knight Cancer Institute, Portland, Oregon
Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients with Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Itacitinib or Ruxolitinib to Improve Efficacy in Patients with Diffuse Large B-Cell Lymphoma Receiving Treatment with CAR T-cell Therapy
Status: Active
Location: Moffitt Cancer Center, Tampa, Florida
Antiangiogenic Therapy for Children with Recurrent Medulloblastoma, Ependymoma and ATRT
Status: Active
Location: Medical University of South Carolina, Charleston, South Carolina
CPX-351 (VYXEOS) for the Treatment of Secondary Myeloid Neoplasms in Patients Under 22 Years Old
Status: Active
Location: Saint Jude Children's Research Hospital, Memphis, Tennessee
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined with BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
Status: Active
Location: City of Hope Comprehensive Cancer Center, Duarte, California
Venetoclax, Tagraxofusp, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients with Philadelphia Chromosome-Positive and/ or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Combination Chemotherapy and Nelarabine in Treating Patients with T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Mini Hyper-CVD with Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for the Treatment of Relapsed B-Cell Acute Lymphocytic Leukemia
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Pembrolizumab Before and After Autologous Stem Cell Transplant for the Treatment of Relapsed or Refractory Classical Hodgkin Lymphoma
Status: Active
Location: University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota
Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma
Status: Active
Location: University of California Davis Comprehensive Cancer Center, Sacramento, California
Olutasidenib Combined with Co-targeted Therapy for the Treatment of Myeloid Cell Cancers in Patients with IDH1 and Co-signaling Gene Mutations
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older with Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Asparaginase Erwinia Chrysanthemi with Chemotherapy for the Treatment of High-Risk Adults with Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Status: Active
Location: City of Hope Comprehensive Cancer Center, Duarte, California
Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients with B Acute Lymphoblastic Leukemia
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Chemoradiotherapy With Targeted Immunotherapy in Pediatric Lymphoma
Status: Active
Location: UF Health Cancer Institute - Gainesville, Gainesville, Florida
Ascorbic Acid and Combination Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, Clonal Cytopenia of Undetermined Significance and Chronic Myelomonocytic Leukemia
Status: Active
Location: Mayo Clinic in Rochester, Rochester, Minnesota
Chemotherapy with or without Total Body Irradiation before Stem Cell Transplant in Treating Patients with Hodgkin or Non-Hodgkin Lymphoma
Status: Active
Location: University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota
Tagraxofusp and Combination Chemotherapy for the Treatment of CD123-Positive Relapsed or Refractory Acute Myeloid Leukemia
Status: Active
Location: Stanford Cancer Institute Palo Alto, Palo Alto, California
Universal Donor Natural Killer Cells for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, KARMA Trial
Status: Active
Location: Nationwide Children's Hospital, Columbus, Ohio
Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington